Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors

INTRODUCTION: Hyperkalemia (potassium >5.0 mEq/L) affects heart failure patients with renal disease regardless of the use of renin–angiotensin–aldosterone system inhibitors (RAASi). The open-label TOURMALINE study showed that patiromer, a sodium-free, nonabsorbed potassium binder, lowers serum po...

Descripción completa

Detalles Bibliográficos
Autores principales: Kloner, Robert A., Gross, Coleman, Yuan, Jinwei, Conrad, Ansgar, Pergola, Pablo E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193203/
https://www.ncbi.nlm.nih.gov/pubmed/30103622
http://dx.doi.org/10.1177/1074248418788334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193203/
https://www.ncbi.nlm.nih.gov/pubmed/30103622
http://dx.doi.org/10.1177/1074248418788334

Ejemplares similares